Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 45 Women only

Identifying factors that affect aspirin's effectiveness in preventing preeclampsia

Official title: Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol

Run by Rockefeller University · NCT05709483 · Data updated 2026-11-12

This study is trying to find out why low-dose aspirin sometimes doesn't work to prevent preeclampsia in women who have had it before during their pregnancies.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment130 (estimated)
SponsorRockefeller University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedApril 13, 2023
Main results expectedNovember 1, 2026
Study endsNovember 1, 2026
Registry record updatedOctober 30, 2025
Trial IDNCT05709483 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18-45 with a prior history of preeclampsia who have taken low-dose aspirin in their subsequent pregnancies.

Probably not a fit

Patients who are under 18 or over 45 years old, or those with a known bleeding disorder or adverse reactions to aspirin, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the genetic, laboratory, and clinical factors that contribute to the failure of low-dose aspirin in preventing preeclampsia, a serious pregnancy complication. Women aged 18-45 with a history of preeclampsia who received aspirin in their subsequent pregnancies will be analyzed to determine the predictors of aspirin failure. The research focuses on the role of genetic variants, particularly in the PAR4 receptor, which may influence platelet function and aspirin efficacy. Participants will undergo platelet function analyses to assess their response to aspirin treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved prevention strategies for preeclampsia, ultimately reducing maternal and fetal morbidity and mortality.

How similar studies have gone: While the approach of investigating genetic factors in aspirin response is innovative, similar studies have shown varying success in understanding aspirin efficacy in different populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Women aged 18-45 years with prior history of preeclampsia who received low dose aspirin in their subsequent gestation and either did or did not have a recurrence of preeclampsia.
2. Aspirin was given in their subsequent pregnancy in a 81 mg dose prior to 16 weeks of gestation, and was taken with a self-reported compliance rate of at least 80%
3. Subsequent pregnancy lasted beyond 20 weeks of gestation
4. Willingness to abstain from non-prescription non-steroidal anti-inflammatory drugs (NSAIDs), which are known to interfere with platelet function assays, for one week prior to platelet function analyses.
5. Healthy controls recruited for SNP assay optimization:

Women aged 18 years or older, with no other specific inclusion criteria that need to be met in order to be enrolled for the study.

Exclusion Criteria:

1. Age \<18 years or \>45 years
2. Any clinically significant adverse reaction to aspirin on prior exposure
3. Known bleeding disorder based on personal or family history
4. History of kidney or liver impairment
5. Current pregnancy
6. Current use of antithrombotic agents (e.g., aspirin, clopidogrel, warfarin, direct acting oral anticoagulants).
7. Chronic hypertension (systolic blood pressure \>140 mmHG or diastolic pressure \>90 mmHG, or use of antihypertensive drugs or diagnosis made by clinician)
8. Diabetes mellitus
9. Current known malignancy
10. History of hemorrhagic stroke
11. Participants may be excluded at the discretion of the investigator for medical, psychological or other reasons
12. Rockefeller students, and Rockefeller employees in the Coller lab, are excluded from participation.
13. Healthy controls:

A. \<18 years of age. B. Participants may be excluded at the discretion of the investigator for medical, psychological or other reasons C. Rockefeller students, and Rockefeller employees in the Coller lab, are excluded from participation.

Where it's running

  • Rockefeller University
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.